CELLphenomics and Charles River Laboratories International, Inc. (NYSE: CRL) announced an agreement, that provides Charles River clients with access to CELLphenomics’ proprietary 3D tumor model platform, PD3D®, which will expand […]
Autor: Firma CELLphenomics
KYAN Technologies, Alentis Therapeutics, and CELLphenomics Join Forces Combining Cutting-edge Optim.AI™ and PD3D® Models to Advance Claudin-1 Expression Research
KYAN Technologies, a vanguard combinatory drug development solutions provider, is thrilled to announce a strategic partnership with Alentis Therapeutics, a clinical-stage biopharmaceutical company developing breakthrough treatments for Claudin-1 positive tumours […]
Berlin scientists use tumor samples drawn from patients with soft tissue sarcomas to individually test their tumor response to ionizing radiation and lay one stepstone towards a translational platform for personalized radiation oncology for rare malignant
Soft tissue sarcomas are a rare group of malignant tumors arising from connective tissue cells, of which more than 70 different subtypes are known to date. The standard therapy for […]
Bowel cancer: Researchers find possible cause for chemoresistance and partially used patient-derived 3D cell culture models for their studies.
Large quantities of the protein IGF2BP2 not only make bowel cancer grow faster, but they also make it resistant to common forms of chemotherapy. This discovery was made by a […]
CELLphenomics’ and KYAN Therapeutics combined platforms provide best-in-class solutions to support the biopharma industry
CELLphenomics and KYAN Therapeutics announced their new partnership today. By combining KYAN’s technology platform, Optim.AI™ – which utilizes artificial intelligence to predict the effects of drug combinations and CELLphenomics‘ proprietary […]
European Union-Funded Project to Result in Novel Treatment Approaches for Several Solid Tumor Types
Indivumed GmbH (“Indivumed”) and CELLphenomics GmbH (“CELLphenomics”) today announced a partnership to create a unique platform for faster and more efficient discovery and validation of therapeutic targets. The new platform […]
Von der Europäischen Union finanziertes Projekt soll zu neuen Therapieansätzen verschiedener solider Tumorarten führen
Indivumed GmbH („Indivumed“) und CELLphenomics GmbH („CELLphenomics“) geben heute ihre Partnerschaft bekannt, in der eine bisher einzigartige Plattform entsteht, die eine schnellere und effizientere Identifizierung und Validierung therapeutischer Targets ermöglichen […]